Molecular Pharmacophore Determination of Lipid Lowering Drugs with the Receptor Mapping Method

被引：4

作者：

Ablise, M. ^{[1
,3
]}

Cartier, A. ^{[2
]}

Siest, G. ^{[3
]}

Visvikis, S. ^{[3
]}

Loppinet, V. ^{[3
]}

机构：

[1] Xinjiang Med Univ, Coll Pharm, Urumqi 830054, Peoples R China

[2] Univ Henri Poincare, Fac Sci, UMR 7565, F-54000 Nancy, France

[3] Univ Henri Poincare, Fac Pharm, INSERM 525, F-54000 Nancy, France

来源：

MINI-REVIEWS IN MEDICINAL CHEMISTRY | 2002年 / 2卷 / 02期

关键词：

molecular modeling; hypolipidemic pharmacophore; EMO and GEOMOS programs; semi-empirical PM3 method; glycyrrhetinic acid derivatives;

D O I：

10.2174/1389557024605528

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Hypolipidemic pharmacophoric moieties of statins, fibrates, ACAT inhibitors and beta-sitosterol analog series were identified by computational modeling, and compared with the computed structure of new potential glycyrrhetinic acid derivatives lipid-lowering drugs. Their electronic and geometric domains, similar to those of fibrates, suggest a fibrate -like mechanism matching biochemical data.

引用

页码：97 / 102

页数：6

共 50 条

[21] Choice of lipid-lowering drugs
不详
MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 1998, 40 (1042): : 117 - 122
[22] Lipid-lowering drugs and cataract
Bezin, J.
Mansiaux, Y.
Pariente, A.
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2017, 31 : 6 - 6
[23] Pharmacogenetics of lipid-lowering drugs
Kivisto, K. T.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2007, 37 : 47 - 47
[24] Carcinogenicity of lipid-lowering drugs
Laws, A
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (19): : 1480 - 1480
[25] LIPID-LOWERING DRUGS AND VIOLENCE
HORROBIN, DF
BRITISH JOURNAL OF PSYCHIATRY, 1989, 154 : 882 - 883
[26] Rhabdomyolysis and lipid-lowering drugs
Tenenbaum, A
Fisman, EZ
Motro, M
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (12): : 1448 - 1448
[27] Lipid-lowering drugs and homocysteine
Landray, MJ
Townend, JN
Martin, S
Martin, U
Wheeler, DC
LANCET, 1999, 353 (9168): : 1974 - 1975
[28] Drug interactions with lipid lowering drugs
Becquemont, L
THERAPIE, 2003, 58 (01): : 85 - 90
[29] Carcinogenicity of lipid-lowering drugs
Newman, TB
Hulley, SB
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (01): : 55 - 60
[30] Lipid lowering drugs and the arterial wall
Paoletti, R
Bernini, F
Corsini, A
Soma, M
MULTIPLE RISK FACTORS IN CARDIOVASCULAR DISEASE: STRATEGIES OF PREVENTION OF CORONARY HEART DISEASE, CARDIAC FAILURE, AND STROKE, 1998, 12 : 19 - 24

← 1 2 3 4 5 →